All In Biotech

Drug Trial Radar · NCT00897949

MK0462 in Treatment of Migraine With Recurrence (MK0462-022)

A Randomized, Triple-Blind, Double-Dummy, Placebo-Controlled, Parallel Groups, Outpatient Study to Examine the Safety and Efficacy of MK0462 10 mg p.o. and MK0462 5 mg p.o. for the Treatment of Acute Migraine and Migraine Recurrence

Last checked: Nov 19, 2026Latest source record: Feb 3, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,473 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,473

Actual

Start

Mar 1995

Primary completion

Jan 1996

Study completion Jul 1996

Sponsor

Lead sponsor
Organon and CoIndustry
Sponsor type
Industry
First posted
May 12, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A study to evaluate rizatriptan/MK0462 (5 and 10 mg) for the treatment of acute migraine attack and treatment of up to two headache recurrences compared to placebo. The long term extension study which pools patients from MK0462-022, -025, and -029 is described in NCT01286207.

Conditions

  • Migraine Headache

Interventions

  • rizatriptan benzoate (MK0462)Drug

    Single dose administration of 5 or 10 mg oral tablet of rizatriptan, taken immediately upon development of acute/severe migraine headache.

  • Comparator: placeboDrug

    Placebo to rizatriptan

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pain Relief at 2 Hours After the Initial Dose of Test DrugTime frame: 2 hours after initial dose of test drug

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.